Source:http://linkedlifedata.com/resource/pubmed/id/17089053
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2006-11-7
|
| pubmed:abstractText |
Clear cell carcinoma (CCC) of the ovary has distinct characteristics showing resistance to conventional platinum-based regimen. Our aim was to evaluate the effects of combination therapy with irinotecan hydrochloride and cisplatin (CPT-P), comparing to regimen with paclitaxel and platinum (TP). We retrospective reviewed 172 patients with complete surgical staging procedures including lymphadenenctomy. Forty-six patients received CPT-P and 126 patients were treated with TP. Survival of the two groups was compared. Between CPT-P group and TP group, there was no significant difference in median age, performance status, FIGO stage, rate of optimal cytoreduction, and follow-up period. There was no significant difference in progression-free survival of patients with stage I tumors (p=0.95) and suboptimally debulked stage II-IV tumors (p=0.92). Although there was no significant difference of overall survival, progression-free survival of CPT-P group was significantly better than that of TP group in optimally debulked stage II-IV (p=0.03). Multiple regression survival analysis revealed CPT-P regimen (p=0.02) and residual tumor diameter (p<0.01) were both independent prognostic factors in stage II-IV tumors. The combination of CPT-P was shown to have a potential therapeutic benefit for advanced CCC of the ovary, especially for cases with optimal debulking surgery. However, this is a limited retrospective study, therefore we recommend that the CPT-P regimen be evaluated in a larger prospective study.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Platinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1021-335X
|
| pubmed:author |
pubmed-author:KigawaJunzoJ,
pubmed-author:KikuchiYoshihiroY,
pubmed-author:KuzuyaKazuoK,
pubmed-author:MoriyaTakuyaT,
pubmed-author:SagaeSatoruS,
pubmed-author:SugiyamaToruT,
pubmed-author:SuzukiMitsuakiM,
pubmed-author:TakanoMasashiM,
pubmed-author:TakeuchiSatoshiS,
pubmed-author:TsudaHiroshiH,
pubmed-author:TsudaHitoshiH,
pubmed-author:UdagawaYasuhiroY,
pubmed-author:YaegashiNobuoN
|
| pubmed:issnType |
Print
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1301-6
|
| pubmed:meshHeading |
pubmed-meshheading:17089053-Adenocarcinoma, Clear Cell,
pubmed-meshheading:17089053-Adult,
pubmed-meshheading:17089053-Aged,
pubmed-meshheading:17089053-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17089053-Camptothecin,
pubmed-meshheading:17089053-Chemotherapy, Adjuvant,
pubmed-meshheading:17089053-Cisplatin,
pubmed-meshheading:17089053-Disease-Free Survival,
pubmed-meshheading:17089053-Female,
pubmed-meshheading:17089053-Gynecologic Surgical Procedures,
pubmed-meshheading:17089053-Humans,
pubmed-meshheading:17089053-Middle Aged,
pubmed-meshheading:17089053-Ovarian Neoplasms,
pubmed-meshheading:17089053-Paclitaxel,
pubmed-meshheading:17089053-Platinum Compounds,
pubmed-meshheading:17089053-Prognosis,
pubmed-meshheading:17089053-Retrospective Studies,
pubmed-meshheading:17089053-Survival Analysis,
pubmed-meshheading:17089053-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
|
| pubmed:affiliation |
Department of Obstetrics and Gynecology, National Defense Medical College, Saitama 359-8513, Japan. m.takano@imperial.ac.uk
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|